EMA Authorised: Azacitidine betapharm (azacitidine) — betapharm Arzneimittel GmbH

View source ↗

Summary

Azacitidine betapharm (azacitidine) has been authorised in the EU for use in myelodysplastic syndromes and various leukemias, with betapharm Arzneimittel GmbH a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myeloid Acute
• Leukemia Myelomonocytic Chronic
• Myelodysplastic Syndromes

Drugs mentioned

• Azacitidine betapharm (azacitidine)

Snippet

Status: Authorised. Therapeutic area: Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute. MAH: betapharm Arzneimittel GmbH. Decision date: 09/01/2024